Ann: USA FDA Grants Orphan Drug Status for PAT-SM, page-53

re: Ann: USA FDA Grants Orphan Drug Status fo... The market needs to accept the statements below as gospel before it can trade at a premium vs. the current discount. A little more evidence maybe, acknowledgement by a third party....come on Mr. Market, work it out, $20M just doesn't cut it here.

"Our trial with PAT-SM6 is producing some very exciting data and it is particularly encouraging to see two patients, with end-stage multiple myeloma, respond so positively to treatment with this novel antibody," commented Patrys' CEO, Dr. Marie Roskrow. "All of the patients being recruited into this trial are resistant to the currently marketed drugs and PAT-SM6 is inducing strong and sustained immunological responses."

"As we move into the final cohort of this trial, Patrys is beginning to attract the attention of potential new investors and commercial partners. We are delighted with the progress of the trial and are most grateful to Dr. Rasche and his colleagues for their continuing clinical support," Dr. Roskrow said.

http://www.medicalnewstoday.com/releases/264774.php